Cargando…
An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2
Soluble forms of angiotensin-converting enzyme 2 (ACE2) have recently been shown to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We report on an improved soluble ACE2, termed a “microbody,” in which the ACE2 ectodomain is fused to Fc domain 3 of the immunoglobulin...
Autores principales: | Tada, Takuya, Fan, Chen, Chen, Jennifer S., Kaur, Ramanjit, Stapleford, Kenneth A., Gristick, Harry, Dcosta, Belinda M., Wilen, Craig B., Nimigean, Crina M., Landau, Nathaniel R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705358/ https://www.ncbi.nlm.nih.gov/pubmed/33326798 http://dx.doi.org/10.1016/j.celrep.2020.108528 |
Ejemplares similares
-
Prophylaxis and treatment of SARS-CoV-2 infection by an ACE2 receptor decoy in a preclinical animal model
por: Tada, Takuya, et al.
Publicado: (2023) -
Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies
por: Zhou, Hao, et al.
Publicado: (2022) -
Restriction of SARS-CoV-2 replication by receptor transporter protein 4 (RTP4)
por: Kaur, Ramanjit, et al.
Publicado: (2023) -
Single-epitope T cell–based vaccine protects against SARS-CoV-2 infection in a preclinical animal model
por: Tada, Takuya, et al.
Publicado: (2023) -
The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition
por: Hattori, Takamitsu, et al.
Publicado: (2021)